What is CUSIP 760273102?

CUSIP 760273102 is the security identifier used in SEC filing datasets for RPTX - Repare Therapeutics Inc. - Common shares, no par value.

Who owns RPTX - Repare Therapeutics Inc. - Common shares, no par value based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

Security Snapshot

Repare Therapeutics Inc. - Common shares, no par value (RPTX) Institutional Ownership

CUSIP: 760273102

13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

$2.59

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common shares, no par value
Symbol: RPTX
Shares outstanding: 42,837,925
SEC-reported price per share: $2.59

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

RPTX - Repare Therapeutics Inc. - Common shares, no par value is tracked under CUSIP 760273102.
13F reference-period holder data is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder data for the Q2 2026 reference period is not available.
Available periods remain in the history table; they do not substitute for the headline period.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

760273102

13F reference period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

RPTX full holder history

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 760273102:

Q1 2026 (0 holders) Q4 2025 (45 holders) Q3 2025 (44 holders) Q2 2025 (49 holders) Q1 2025 (49 holders) Q4 2024 (53 holders) Q3 2024 (56 holders) Q2 2024 (60 holders) Q1 2024 (70 holders) Q4 2023 (69 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

RPTX

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Shay Capital LLC	6.7%		$7,462,367		2,870,141		Shay Capital LLC	20 Jan 2026
ARK Investment Management LLC	4.7%		$2,199,996		1,999,996		ARK Investment Management LLC	31 Dec 2024
MPM BioVentures 2014, L.P.	4.6%	-10%	$2,135,366	-$228,990	1,941,242	-9.7%	ANSBERT GADICKE	31 Jan 2025

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

n/a

Rows shown

1-25 of 29

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q1	0	$0	-$65,108,559	$0	$0	$2.59	0
2025 Q4	25,162,567	$65,418,419	+$649,419	$514,540	$653,380	$2.60	45
2025 Q3	27,272,759	$47,994,480	-$585,720		$190,256	$1.76	44
2025 Q2	27,751,924	$38,574,670	-$1,382,414	$0	$156,514	$1.39	49
2025 Q1	29,510,013	$29,086,692	-$1,273,490	$887	$0	$0.99	49
2024 Q4	30,627,189	$40,115,894	-$3,245,437	$0	$1,250	$1.31	53
2024 Q3	32,384,039	$111,394,012	-$4,678,067	$1,032	$0	$3.44	56
2024 Q2	33,787,071	$111,563,077	-$7,679,698	$58,410	$5,610	$3.30	60
2024 Q1	35,509,240	$167,234,827	-$6,368,867	$12,717	$77,244	$4.71	70
2023 Q4	36,516,609	$266,618,743	+$7,114,924	$74,460	$312,440	$7.30	69
2023 Q3	36,251,577	$437,732,348	+$5,862,256	$769,496	$12,181,472	$12.08	75
2023 Q2	35,816,579	$379,155,366	+$27,699,133	$22,218	$80,408	$10.58	77
2023 Q1	33,203,752	$326,704,500	-$3,869,255	$33,456	$173,184	$9.84	77
2022 Q4	33,439,349	$491,913,773	+$9,270,562	$17,652	$1,245,462	$14.71	81
2022 Q3	32,825,390	$398,104,252	-$27,705,169	$0	$1,866,000	$12.13	68
2022 Q2	33,241,732	$451,682,656	+$10,057,776	$304,000	$2,760,000	$13.99	71
2022 Q1	32,606,123	$464,339,399	-$15,992,556	$0	$1,749,000	$14.24	61
2021 Q4	32,686,703	$689,483,446	+$73,866,430	$217,000	$207,000	$21.09	65
2021 Q3	26,958,565	$707,727,594	+$8,752,319	$627,000	$622,000	$26.24	66
2021 Q2	26,541,561	$828,248,052	+$17,346,878	$268,000	$518,000	$31.18	61
2021 Q1	25,991,734	$797,739,395	+$23,245,092			$30.69	64
2020 Q4	27,148,766	$931,197,865	+$31,433,436			$34.30	61
2020 Q3	23,874,907	$734,608,729	+$25,936,109			$30.77	37
2020 Q2	22,517,975	$698,109,449	+$698,106,449			$31.02	47
2020 Q1	100	$3,000				$30.00	1